Bruce Booth, Director at Kymera Therapeutics, Inc. (KYMR), sold 285,684 shares at $119.71 ($34.8M) on 2026-06-25, disclosed to the SEC on 2026-06-25.
Scheduled sale ($34.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $119.71 | 37,179 | $4.5M | 12.8% |
| 2 | $119.71 | 5,144 | $616K | 1.8% |
| 3 | $120.66 | 15,660 | $1.9M | 5.4% |
| 4 | $120.66 | 112,299 | $13.5M | 38.9% |
| 5 | $121.38 | 5,689 | $691K | 2.0% |
| 6 | $121.38 | 40,774 |
| $4.9M |
| 14.2% |
| 7 | $122.67 | 4,977 | $611K | 1.8% |
| 8 | $122.67 | 698 | $86K | 0.2% |
| 9 | $123.62 | 10,860 | $1.3M | 3.9% |
| 10 | $123.62 | 1,517 | $188K | 0.5% |
| 11 | $124.61 | 1,639 | $204K | 0.6% |
| 12 | $124.61 | 11,711 | $1.5M | 4.2% |
| 13 | $125.82 | 3,716 | $468K | 1.3% |
| 14 | $125.82 | 522 | $66K | 0.2% |
| 15 | $126.71 | 223 | $28K | 0.1% |
| 16 | $126.71 | 1,609 | $204K | 0.6% |
| 17 | $127.37 | 25,075 | $3.2M | 9.2% |
| 18 | $127.37 | 3,507 | $447K | 1.3% |
| 19 | $128.69 | 305 | $39K | 0.1% |
| 20 | $128.69 | 2,197 | $283K | 0.8% |
| 21 | $129.61 | 46 | $6K | 0.0% |
| 22 | $129.61 | 337 | $44K | 0.1% |
| Total | $121.86 avg | 285,684 | $34.8M | 100% |
| Filing → |
| KYMR | SELL | 2026-06-30 | $3.4M | — | Filing → |
| KYMR | SELL | 2026-06-25 | $44.0M | — | Filing → |
| KYMR | SELL | 2026-06-22 | $45.3M | — | Filing → |